Is the Sotorashib AMG510 produced by Bangladesh Ziska the same as the original one?

Sotoracib (AMG510)is the first targeted drug to treat KRAS G12 mutations and is used to treat adult patientsKRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). This medicine has been produced by Bangladesh Zisika Pharmaceuticals and has been launched in Bangladesh in 2022 with government approval.

The original drug Sotorasibu is available in Hong Kong, and the retail price of the European version120 mg 240 tablets4 is produced by Ziskar Pharmaceuticals in Bangladesh. The retail price of 120 mg 56 tablets is around 1,000. There is a big price gap between generic drugs and original drugs, but the ingredients and doses are the same, so there is not much difference. There is no difference between the officially marketed generic drugs and the original drugs. Patients can choose drug versions based on their financial situation.

Sotoraxib is a CYP3A4 inducer and coadministration of sotoraxib with a CYP3A4 substrate may decrease its plasma concentration, which may reduce the efficacy of the substrate. Avoid coadministration of sotolaxib with CYP3A4 sensitive substrates as minimal concentration changes may result in substrate therapeutic failure, if coadministration cannot be avoided, increase the dose of the sensitive CYP3A4 substrate according to its prescribing information. The safety and effectiveness of sutolaxib in pediatric patients have not been established. In CodeBreaK 100, sotolaceib is taken orally once daily 960 Of the 357 patients with any tumor type, 46% were 65years and older, 10% were 75years and older, and no overall difference in safety or effectiveness was observed between older patients and younger patients. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.